OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
OptimizeRx CorporationNASDAQ: OPRX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $13.47M fell 12.8% year over year, ahead of the -16.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Operating expenses amounted to 52.3% of revenue in FY2025, down 27.1 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -12.8% holds above the trailing-twelve-month pace of -16.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 57.21M USD
- Year-over-year change
- -21.7%
- 4-year CAGR
- +12.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.21M | -21.7% |
| FY2024 | 2024-12-31 | 73.08M | +5.5% |
| FY2023 | 2023-12-31 | 69.3M | +35.2% |
| FY2022 | 2022-12-31 | 51.26M | +45.3% |
| FY2021 | 2021-12-31 | 35.28M | — |
Operating Expenses vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.5% is the 9th highest of 10, against a peer median of +19.1%.
- Operating expenses amounts to 55.5% of revenue for OPRX, versus a peer median of 97.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $307.53M USD | +12143.5% | +209.6% | 7845.8% | |
| LTM Mar 2026 | $156.61M USD | -4.5% | +5.9% | 45.3% | |
| LTM Mar 2026 | $153.52M USD | +7.0% | +21.3% | 120.4% | |
| LTM Mar 2026 | $126.37M USD | +15.3% | -0.1% | 155.7% | |
| LTM Feb 2026 | $117.13M USD | +193.9% | +60.7% | 145.4% | |
| LTM Mar 2026 | $102.62M USD | +49.5% | +10.1% | 75.1% | |
| LTM Mar 2026 | $59.55M USD | -16.5% | +3.7% | 55.5% | |
| LTM Mar 2026 | $57.87M USD | +19.1% | +4.5% | 41.7% | |
| LTM Mar 2026 | CA$31.41M CAD | +467.7% | -2.4% | — | |
| LTM Mar 2026 | $13.47M USD | -98.7% | -3.1% | 5.7% | |
| Peer median (excluding OPRX) | — | +19.1% | +5.9% | 97.8% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.29M | 62.45M | 71.52M | 92.13M | 109.43M |
| Cost of Revenue | 25.65M | 23.48M | 28.62M | 32.75M | 40.16M |
| Gross Profit | 35.64M | 38.97M | 42.9M | 59.38M | 69.27M |
| Gross Margin | 58.1% | 62.4% | 60.0% | 64.5% | 63.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 33.19M | 49.24M | 58.02M | 61.27M | 50.25M |
| Operating Expenses | 35.28M | 51.26M | 69.3M | 73.08M | 57.21M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| EBITDA | 2.34M | (9.42M) | (21.31M) | (8.9M) | 16.57M |
| EBITDA Margin | 3.8% | -15.1% | -29.8% | -9.7% | 15.1% |
| Operating Income | 361.1K | (12.29M) | (26.4M) | (13.71M) | 12.06M |
| Operating Margin | 0.6% | -19.7% | -36.9% | -14.9% | 11.0% |
| Interest Income | 16.98K | 852.3K | 2.19M | 329K | 353K |
| Interest Expense | 0 | 0 | 1.45M | 6.16M | 5.29M |
| Other Income / Expenses | 16.98K | 852.3K | 1.24M | (5.68M) | (5.11M) |
| Income Before Tax | 378.08K | (11.44M) | (25.16M) | (19.39M) | 6.95M |
| Pre-Tax Margin | 0.6% | -18.3% | -35.2% | -21.0% | 6.4% |
| Income Tax Expense | 0 | 0 | (7.6M) | 725K | 1.82M |
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Net Margin | 0.6% | -18.3% | -24.6% | -21.8% | 4.7% |
| EPS (Basic) | 0.02 | (0.64) | (1.03) | (1.10) | 0.28 |
| EPS (Diluted) | 0.02 | (0.64) | (1.03) | (1.10) | 0.27 |
| Weighted Avg Shares | 17.23M | 17.78M | 17.12M | 18.29M | 18.56M |
| Weighted Avg Shares (Diluted) | 17.69M | 17.78M | 17.12M | 18.29M | 19M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.